Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levofloxacin

FDA-approved product (tablet, oral), marketed as Iquix, Levaquin, Levaquin In Dextrose 5% In Plastic Container and 3 more.

Registered studies
50+
Lab records
143
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levofloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Pneumonia
  • Respiratory tract infectious disorder
  • Sinusitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
FDA pharmacologic class
Fluoroquinolone Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA12; WHO ATC S01AE05; FDA class Fluoroquinolone Antibacterial

Repurposing investigation

Levofloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis91.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 7 of 7 lab records
  • K. pneumoniae: measured active in 128 of 131 lab records
  • M. tuberculosis: measured active in 4 of 4 lab records
Open Levofloxacin in ChEMBL Registered studies below
Show the 143 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levofloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)

    NCT07528417 · start 2026-09-01

    Registered record
    Registry ID
    NCT07528417
    Conditions
    Myeldysplastic Syndrome (MDS); MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET); Acute Myeloid Leukemia
    Interventions
    Levofloxacin; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2028-04-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeldysplastic Syndrome (MDS); MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET); Acute Myeloid Leukemia
    InterventionLevofloxacin; Usual Care
    PhasePhase 2
    Registry statusNot yet recruiting

  • Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease

    NCT07529899 · start 2026-09

    Registered record
    Registry ID
    NCT07529899
    Conditions
    Dry Eye Disease (DED)
    Interventions
    Standard of Care (SOC); Lyophilized Amnion Membrane Disc Allograft
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2026-09
    Completion
    2027-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease (DED)
    InterventionStandard of Care (SOC); Lyophilized Amnion Membrane Disc Allograft
    PhasePhase 4
    Registry statusWithdrawn

  • Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing

    NCT07533422 · start 2026-05-12

    Registered record
    Registry ID
    NCT07533422
    Conditions
    HELICOBACTER PYLORI INFECTIONS; Rescue Therapy for Helicobacter Pylori
    Interventions
    Personalized treatment based on the results of fecal antimicrobial resistance gene testing; Conventional Quadruple Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-12
    Completion
    2027-02-01
    Enrolment
    531

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS; Rescue Therapy for Helicobacter Pylori
    InterventionPersonalized treatment based on the results of fecal antimicrobial resistance gene testing; Conventional Quadruple Therapy
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Fecal Molecular Susceptibility-guided Hp First-line Therapy

    NCT07405684 · start 2026-02-28

    Registered record
    Registry ID
    NCT07405684
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-02-28
    Completion
    2028-12-31
    Enrolment
    544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    Intervention7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    PhasePhase 4
    Registry statusNot yet recruiting

  • 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

    NCT07198685 · start 2025-09-30

    Registered record
    Registry ID
    NCT07198685
    Conditions
    Treat to Target; Treatment Duration
    Interventions
    bedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin; Cycloserine; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-09-30
    Completion
    2028-09-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreat to Target; Treatment Duration
    Interventionbedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin +2 more
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis

    NCT05867654 · start 2024-07-31

    Registered record
    Registry ID
    NCT05867654
    Conditions
    Osteomyelitis of Jaw
    Interventions
    Amoxicillin-clavulanate 875mg/125mg q12hrs; oral clindamycin 300mg q6hrs; Levofloxacin 750mg QID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-07-31
    Completion
    2025-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis of Jaw
    InterventionAmoxicillin-clavulanate 875mg/125mg q12hrs; oral clindamycin 300mg q6hrs; Levofloxacin 750mg QID
    PhasePhase 4
    Registry statusUnknown

  • D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy

    NCT06049758 · start 2024-01-02

    Registered record
    Registry ID
    NCT06049758
    Conditions
    Blood Loss; Intensive Care; Anastomotic Leakage; Lymph Node Disease; Survival; Blood Transfusion
    Interventions
    LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention); Enoxaparin 40 Mg/0.4 mL Injectable Solution; Levofloxacin 500mg; LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-01-02
    Completion
    2030-01-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlood Loss; Intensive Care; Anastomotic Leakage; Lymph Node Disease +2 more
    InterventionLAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention); Enoxaparin 40 Mg/0.4 mL Injectable Solution; Levofloxacin 500mg; LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke

    NCT05799326 · start 2023-06-30

    Registered record
    Registry ID
    NCT05799326
    Conditions
    Acute Ischemic Stroke
    Interventions
    Levofloxacin; Levofloxacin simulant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-06-30
    Completion
    2024-12-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionLevofloxacin; Levofloxacin simulant
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT

    NCT06088316 · start 2023-02-10

    Registered record
    Registry ID
    NCT06088316
    Conditions
    Helicobacter Pylori Infection; Helicobacter Pylori Eradication
    Interventions
    group A : Amoxicillin Esomeprazole HDDT; group-B : Levofloxacin triple therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-02-10
    Completion
    2024-02
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Helicobacter Pylori Eradication
    Interventiongroup A : Amoxicillin Esomeprazole HDDT; group-B : Levofloxacin triple therapy
    PhasePhase 4
    Registry statusUnknown

  • Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy

    NCT06199778 · start 2022-06-01

    Registered record
    Registry ID
    NCT06199778
    Conditions
    Traumatic Brain Injury
    Interventions
    Rehabilitation therapy; Intermittent Oro-esophageal Tube Feeding; Nasogastric tube feeding; Reserpine; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2022-06-01
    Completion
    2023-06-15
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraumatic Brain Injury
    InterventionRehabilitation therapy; Intermittent Oro-esophageal Tube Feeding; Nasogastric tube feeding; Reserpine +1 more
    PhaseNot applicable
    Registry statusTerminated

  • Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection

    NCT05332444 · start 2022-04-11

    Registered record
    Registry ID
    NCT05332444
    Conditions
    Helicobacter Pylori Infection
    Interventions
    susceptibility-guided tailored therapy (Group A); guidelines-recommended empiric therapy (Group B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-04-11
    Completion
    2026-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionsusceptibility-guided tailored therapy (Group A); guidelines-recommended empiric therapy (Group B)
    PhasePhase 4
    Registry statusRecruiting

  • Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin

    NCT05129176 · start 2021-11-23

    Registered record
    Registry ID
    NCT05129176
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Levofloxacin; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-11-23
    Completion
    2022-11
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionLevofloxacin; Metronidazole
    PhasePhase 4
    Registry statusUnknown

  • Helicobacter Pylori Eradication and Follow-up

    NCT05061732 · start 2021-09-30

    Registered record
    Registry ID
    NCT05061732
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Rabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin; Levofloxacin; Amoxicillin; Metronidazole; Doxycycline; Tetracycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-09-30
    Completion
    2026-06-30
    Enrolment
    4,447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionRabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin +5 more
    PhasePhase 4
    Registry statusUnknown

  • Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections

    NCT04488458 · start 2021-08-15

    Registered record
    Registry ID
    NCT04488458
    Conditions
    Prosthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    Interventions
    MIC or MBEC+MIC based treatment algorithm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-15
    Completion
    2023-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    InterventionMIC or MBEC+MIC based treatment algorithm
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults

    NCT05313750 · start 2021-06-30

    Registered record
    Registry ID
    NCT05313750
    Conditions
    Acute Exacerbation of Bronchiectasis
    Interventions
    anti-infective therapy sitafloxacin; anti-infective therapy levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06-30
    Completion
    2024-06-30
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Exacerbation of Bronchiectasis
    Interventionanti-infective therapy sitafloxacin; anti-infective therapy levofloxacin
    PhasePhase 4
    Registry statusUnknown